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Abstract
Introduction: Intensive care unit-acquired weakness (ICU-AW) is often observed in critically ill patients with prolonged intensive
care unit (ICU) stay. We hypothesized that evolving metabolic abnormalities during prolonged ICU stay are reﬂected by changing
nutrient patterns in blood, urine and skeletal muscle, and that these patterns differ in patients with/without ICU-AW and between
patients with/without sepsis.
Methods: In a prospective single-center observational trial, we aim to recruit 100 critically ill patients (ICU length of stay ≥ 5 days)
with severe sepsis/septic shock (“sepsis group”, n=50) or severe head trauma/intracerebral hemorrhage (“CNS group”, n=50).
Patients will be sub-grouped for presence or absence of ICU-AW as determined by the Medical Research Council sum score. Blood
and urine samples will be collected and subjected to comprehensive nutrient analysis at different time points by targeted quantitative
mass spectrometric methods. In addition, changes in muscular tissue (biopsy, when available), muscular architecture (ultrasound),
electrophysiology, body composition analyses (bioimpedance, cerebral magnetic resonance imaging), along with clinical status will
be assessed. Patients will be followed-up for 180 and 360 days including assessment of quality of life.
Discussion:Key objective of this trial is to assess changes in nutrient pattern in blood and urine over time in critically ill patients with/
without ICU-AW by using quantitative nutrient analysis techniques. Peer-reviewed published NAChO data will allow for a better
understanding of metabolic changes in critically ill patients on standard liquid enteral nutrition and will likely open up new avenues for
future therapeutic and nutritional interventions.
Abbreviations: ACCP = American college of chest physicians, CIM = critical illness myopathy, CIP = critical illness
polyneuropathy, CIPM = critical illness polyneuromyopathy, CMAP = compound action muscle potential, CNS = central nervous
system, CTU= clinical trial unit, D= day (day of trial), eCRF= electronic case report ﬁles, GCP= good clinical practice, ICF= informed
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consent form, ICU = intensive care unit, ICU-AW = intensive care unit - acquired weakness, IMC = intermediate care unit, IRB =
institutional review board, MRC =medical research council, MRI =magnetic resonance imaging, RRT = renal replacement therapy,
SCCM = society of critical care medicine, US = ultrasound, V = visit (trial visit), VIDD = ventilator-induced diaphragmatic dysfunction,
VL = vastus lateralis.
Keywords: brain injury, ICU acquired weakness, metabolic pathways, metabolomics, nutrition, proteomics, sepsis
1. Introduction
ICU acquired weakness (ICU-AW),[1–6] or critical illness myo-/
poly-neuropathy (CIP/CIM/CIPM), is a key complication in
critical illness and is associated with increased morbidity and
mortality.[1–3,7,8] Data indicate that up to 80% of ICU patients
develop some form of neuromuscular dysfunction during ICU
stay.[6] Importantly, ICU-AW and ventilator-induced diaphrag-
matic dysfunction (VIDD)[9–11] are associated with increased
resource use, health care costs,[1–6,12–14] and prolonged hospital-
ization.[5–7,15] Although ICU-AW is a frequent complication of
critical illness with important medical and economic consequen-
ces, only few data is available on evolving nutrient patterns in
affected patients. While physical inactivity and impaired motor
neurone and muscle ﬁber action potential transmission will
inevitably result in loss of muscle mass, metabolic abnormalities
may also contribute to the disease.[16] Among others, sepsis/septic
shock and/or multi-organ failure can be considered key risk
factors for ICU-AW.[3,5,6,12] Sepsis-induced myopathy and/or
cytokine-mediated axonal neuropathy was shown to represent
one underlying pathway leading to ICU-AW.[3,17–19]
Large-scale data on nutrient patterns in critically ill patients is
currently lacking, with andwithout, ICU-AW.Wewill, therefore,
study nutrient patterns over time, including amino acids, fatty
acids, organic acids, lipo- and hydrosoluble vitamins, minerals,
using comprehensive nutrient analysis in affected patients.[20,21]
In addition, we will explore the immune system/metabolic
interface, for example, in tryptophan catabolism.[22–24] In the
current exploratory study, we will assess ICU patients with a
particularly high incidence of ICU-AW (sepsis/septic shock,
“sepsis group”) and patients with a presumed low ICU-AW
incidence (severe head trauma and/or intracerebral hemorrhage,
“CNS group”).
2. Objectives
2.1. Primary objectives
 Assessment of nutrient levels in blood over time in ICU long
stayers (deﬁned as patients with ICU length of stay ≥ 5 days)
with ICU-AW (“ICU-AW group”, deﬁned as MRC sum
score<48) vs without ICU-AW (“no-ICU-AW group”).
 Assessment of nutrient levels in blood over time in ICU long
stayers (deﬁned as patients with ICU length of stay ≥ 5 days)
with severe sepsis/septic shock (“sepsis group”, according to
1992ACCP/SCCM consensus deﬁnitions) vs without sepsis
(“CNS group”) at ICU admission.
2.2. Secondary objectives
 Assessment of nutrient levels over time in urine in ICU long
stayer (“sepsis group” and “CNS group”) with & without
ICU-AW and between sepsis and CNS patients.
 Assessment of nutrient levels over time in muscle biopsy
samples in all study groups (ie, “ICU-AW” vs “no-ICU-AW”
and “sepsis group” vs “CNS group”), depending upon
availability of a signiﬁcant number of biopsies per group.
3. Methods
The “Nutrient pattern analysis in critically ill patients using
Omics technology- a prospective single-center observational
study” (NAChO) is a single-center prospective observational
study performed in a tertiary care academic medical center
department of intensive care (Department of Intensive Care
Medicine, Inselspital, Bern University Hospital, University of
Bern, Switzerland). Recruitment started in December 2016
(ongoing), actual protocol version is V5.0, dated March 22,
2017. Each patient attends a minimum of 1 visit (V0 [screening
visit] to be performed at Day 5) and a maximum of 16 visits,
depending on the date of ICU discharge (Fig. 1). A maximum of
13 visits imply study speciﬁc sampling (venous blood and/or 24 h
urine). Day 1 (D1) is the day the patient is admitted to the
Intensive Care Unit. Day 5 (D5) is the day patient is considered as
“ICU long stayer”, which triggers V0, the screening visit. Day 6
(D6) is considered the baseline visit (V1) (Fig. 1).
Prior to study inclusion, the Investigator and/or his/her
designee will explain the trial fully to the prospective patient
or his/her legal representative (in case a patient is unable to
provide consent). In case of willingness to participate, the patient
or his/her legal representative and the Investigator or his/her
designee will sign the Informed Consent Form (ICF). A separate,
additional ICF will be provided for muscle biopsies. Patients can
thus participate in NAChO without providing informed consent
for muscle biopsies. The patient’s suitability for the trial will be
conﬁrmed by the inclusion/exclusion criteria (see below). Study
procedures are performed according to the planned time schedule
with strict adherence to visit intervals (Fig. 1). Patients will receive
trial visits (or study-speciﬁc measures) as described below, as long
as they are in the ICU or Intermediate care (IMC) and informed
consent is not retracted. Patients will receive standard enteral
liquid nutrition, typically adapted to needs determined by indirect
calorimetry. A SPIRIT checklist and Figure based on SPIRIT
recommendations is attached.
3.1. Approvals
This study was approved by the respective competent local ethics
committee on human research (Kantonale Ethikkomission, KEK,
Bern Switzerland, approval number 2016–00732. Informed
consent is achieved from all participants/legal representatives.
3.2. Population
We target to include 100 critically ill patients (n=50 with severe
sepsis/septic shock and n=50 with severe head trauma and/or
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intracerebral hemorrhage of any source) with ICU length of stay
≥ 5 days.
The following inclusion criteria apply:
 Age ≥ 18 years.
 Written informed consent obtained from the patient’s legal
representative.
 Individuals diagnosed with severe head trauma (initial
Glasgow Coma Score<7) or intracerebral hemorrhage
(“CNS group”) or severe sepsis/septic shock (“sepsis group”;
deﬁned by ACCP/SCCM consensus deﬁnitions) at any time
from ICU admission until day 5 (ie, day of screening).
 Patient on the ICU for ≥ 5 days (“ICU long stayer”).
The following exclusion criteria apply:
 Language other than German or French.
 Institutionalized Individuals (eg, prisoners, severe pre-existing
mental incapacity).
 Patients with known pre-existing neurological or psychiatric
disease that will make informed consent likely impossible.
 Patients with known pregnancy/known to be lactating (no
pregnancy testing).
 Patients on extracorporeal membrane oxygenation (ECMO).
 Clinical signsof pre-existingmalnutrition (BodyMass Index<18).
 Pre-existing evidence for history of anorexia or bulimia.
 Parenteral nutrition received within last 5 days (for more than
12h) or evidence for parental nutrition needed within next 7
days.
 Terminal disease (ie, life expectancy<14 days).
 Patients with active malignancy.
 Patients on biologicals interfering with metabolism (eg,
inﬂiximab).
 Patients on chronic steroid medication (ie, prednisone equiva-
lent dose>10mg/day).
 Patients on neuromuscular blocking agents on a regular basis
(ie, on a repetitive basis within last 48h or evidence for need
within next 7 days).
 At screening (day 5): prescribed caloric intake substantially
higher (ie,>150% of caloric need of indirect calorimetry) than
indirect calorimetric results (in intubated patients) or that is,
standard-of-care (25Kcal/kg body weight/day).
 Severe adipositas (Body Mass Index>40).
 Known pre-existing allergy to standard enteral formulae.
 Patient previously enrolled to an interventional trial that is not
considered standard-of-care (eg, investigation of new medica-
tion/drug or medical devices).
3.3. Patient discontinuation criteria
A patient may be discontinued prematurely for the following
reasons (patients who discontinue before completing the trial will
not be replaced):
 Patient requests to leave the trial.
 If, in the Principal Investigator’s opinion, continuation in the
trial would be detrimental to the patients’ well-being.
 Sponsor or Independent Ethics Committee (EC)/Institutional
Review Board (IRB) decides to terminate trial for signiﬁcant
reasons.
3.4. Outcome measures
3.4.1. Primary endpoints.
 Differences in blood (plasma/serum) nutrient levels over time
in patients with/without ICU-AW (ie, “ICU-AW” vs “no-ICU-
AW” groups. Primary comparison of interest is between day 6
(baseline visit) and day 14.
Study visits 
 
V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 
DAYS IN ICU D1 D5 D6 D7 D8 D9 D10 D12 D14 D16 D18 D20 D22 D26 D30 M6 M12 
Schedule ICU 
admission 
Screening 
inclusion 
Baseline                         6 Mo 
12 
Mo 
Demographics X 
                
Clinical data X X X X X X X X X X X X X X X 
  
Routine laboratory data (recorded when available) * X X X X X X X X X X X X X X X 
  
Study specific blood sampling (incl. nutrients) * 
  
X X X X X X X X X X X X X 
  
Study specific blood sampling for immune status * 
  
X 
 
X 
   
X 
   
X 
    
Study specific 24 h urine sampling ** 
  
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
  
Muscle biopsy */ # 
  
X 
     
X 
        
Ultrasound (US): e.g. muscular architecture * 
  
X 
 
X 
 
X 
 
X 
   
X 
 
X 
  
ICU-AW: CIP/CIM assessment (incl. MRC sum score)* 
  
X 
 
X 
   
X 
 
X  
 
X X X 
  
Delirium assessment: CAM-ICU * 
  
X 
 
X 
   
X 
 
X 
 
X X X 
  
Electrophysiological examination * 
  
X 
     
X 
   
X 
    
Indirect Calorimetry (if intubated) * 
  
X 
 
X 
 
X X X 
 
X 
 
X X X 
  
cMRI *** 
  
X 
              
Bioimpedance * 
  
X 
 
X 
 
X X X 
 
X 
 
X X X 
  
Quality of Live: SF36 questionnaire 
  
X 
            
X X 
Figure 1. SPIRIT Figure indicating visits/study-speciﬁc assessments.
∗
Sampling/assessment can only occur when subject hospitalized in Dept. of Intensive Care
Medicine (ie, on their ICUs or IMC).
∗∗
Maximum target volume per study speciﬁc 24h urine sample is 30 ml. Sampling can only occur when subject hospitalized in
ICU or IMC.
∗∗∗
In a subgroup of patients (male, n=15). # Depending on presence of separate consent form signed.
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 Differences in blood (plasma/serum) nutrient levels over
time in patients in “sepsis group” vs “CNS group”. Primary
comparison of interest is between days 6 (baseline visit) and 14.
3.4.2. Secondary endpoints.
 Differences in urine nutrient levels over time in patients with/
without ICU-AW (ie, “ICU-AW” vs “no-ICU-AW” groups.
Primary comparison of interest is between days 6 (baseline
visit) and 14.
 Differences in urine nutrient levels over time in patients in
“sepsis group” vs “CNS group”. Primary comparison of
interest is between days 6 (baseline visit) and 14.
 Subgroup analysis: differences in nutrient levels at days 6
(baseline visit) and 14 in muscle biopsy samples (if available) of
ICU long stayer patients in study groups (ie, “ICU-AW” vs
“no-ICU-AW” and “sepsis group” vs “CNS group”).
3.4.3. Exploratory endpoints. Please refer to supplemental
content, http://links.lww.com/MD/C737.
3.5. Sample collection and sample handling
Blood samples are collected in the morning and immediately
stored at the recommended temperature (usually on ice). Blood
collection tubes, intermediate tubes and sample vials remain at
the recommended temperature during pre-analytical sample
handling (usually on ice). Sample aliquots for vitamin C and
liposoluble vitamins are prepared using speciﬁc antioxidants to
avoid oxidation of the vitamins. All aliquots are stored at 80°C
until the start of analyses. For collection of 24h urine samples, the
urine is collect in standard of care urine collectors. Urine
collectors are then completely discharged in pre-cleaned plastic
containers, sealed and homogenized by gently shaking. Subse-
quently, the speciﬁc density and total weight of the urine are
determined before aliquots for analysis are collected and stored at
80°C. Muscle biopsies (open surgical biopsy from Musculus
vastus lateralis) will be handled according to routine pre-
analytical requirements for histological staining and nutrient
analysis.
3.6. Study speciﬁc analysis and clinical measures
3.6.1. Laboratory analyses. In brief, we aim to quantify the
following levels of nutrients by using mass spectrometry and
clinical chemistry platforms (please also refer to supplemental
content, http://links.lww.com/MD/C737)[25,26]: Blood (plasma/
serum): fatty acids, amino acids and metabolites, organic acids,
electrolytes/minerals, vitamins, routine clinical markers (phos-
phate, albumin, pre-albumin, total protein, alanine aminotrans-
ferase, total bilirubin, creatinine kinase, alkaline phosphatase,
creatinine, urea, lipase, cholesterol, C-reactive protein/inﬂamma-
tory markers, ferritin, total IgG, cortisol, ceruloplasmin,
transferrin, parathyroid hormone and exploratory markers of
muscle metabolism.
Urine: speciﬁc density, electrolytes/minerals, creatinine, uric
acid, inﬂammatory markers.
Muscle: should circulating nutrient signatures associated with
ICU-AW be identiﬁed, complementary analysis of intramuscular
levels of speciﬁc nutrients (eg, minerals, amino acids) will be
performed, depending on sample availability.
3.6.2. Imaging: ultrasound, cMRI. Ultrasound (US) is a bedside
tool used in this study to assess skeletal muscle architecture and
muscle wasting in ICU patients.[27] Proximal muscles of the lower
extremities are particularly prone to muscle wasting.[28] The
Musculus vastus lateralis (VL) is easily accessible and allows
reliable and reproducible recording of muscle thickness. US
assessments will be performed using a 7.5 Mhz linear probe with
patients in the supine position with both legs extended.Whenever
possible, the right leg will be investigated at 3/5 of the distance
between anterior superior iliac spine and the lateral superior
patellar border (longitudinal axis, perpendicular to skin). The
following US parameters will be assessed: VL muscle thickness
and thickness of subcutaneous tissue (both in long axis, edge to
edge). Image intensity, fascicle length and pennation angle will be
available in secondary analyses. Using cMRI imaging, tensor-
based morphometry will be assessed to investigate structural
changes in brain morphology.
3.6.3. Bioimpedance. Bioimpedance (BIA corpus RX 4004,
Medi-Cal, Karlsruhe, Germany) will be used for body composi-
tion analysis. The following indices will be assessed: basal
metabolic rate (BMR), extracellular mass (ECM), body cell mass
(BCM), fat mass (FM), fat free mass (FFM), total body water
(TBW), extracellular water (ECW), intracellular water (ICW),
water balance, phase angle (PA), vectorial data (reactance,
resistance).
3.6.4. Clinical assessments: ICU-AW, delirium, indirect
calorimetry. ICU-AW will be assessed clinically as determined
by the Medical Research Council (MRC) sum score (ICU-AW
deﬁned as MRC sum score<48). Delirium will be assessed by
using the Confusion Assessment Method for the Intensive Care
Unit (CAM-ICU).[29] Indirect calorimetry will be performed in
cases patients are intubated using standard mechanical ventila-
tors (Servo-I, Maquet, Getinge, Sweden).
3.6.5. Electrophysiological examination (ENMG). Electro-
physiologic examinations (conventional nerve conduction stud-
ies, conventional electromyography) will be performed. For
assessment of critical illness polyneuropathy (CIP), occurrence of
axonal motor and sensory polyneuropathy will be used for
diagnosis. Absence of a decremental response on repetitive nerve
stimulation will be checked for to rule out concurrent
neuromuscular junction dysfunction. The following anatomical
sites will be assessed: Nn. peroneus, suralis, medianus. For
assessment of critical illness myopathy (CIM), additional EMG
and direct muscle stimulation (and calculation of the compound
muscle action potential (CMAP) ratio nerve vs muscle stimula-
tion) will be performed from the M. tibialis anterior. CMAP
amplitudes less than 80% of the lower limit of normal in 2 or
more nerves without conduction block and sensory nerve action
potential amplitudes more than 80% of the lower limit of normal
will be considered relevant for diagnosis of CIM in parallel to
typical ﬁndings in EMG and a pathological nerve/muscle CMAP
ratio. In all investigations, the right extremity will preferentially
be investigated.
3.7. Data collection and management
Collected data will be entered in the database via electronic case
report ﬁles (eCRF). Web-based access to the database is provided
on a 24/7 basis. Data will be encoded by using a unique patient
identiﬁcation number. Data will be handled according to the
requirements of local data protection authorities and respective
ethical committees. All data will be stored in a protected
environment for a minimum of 10 years and anonymized if
requested by the authorities. The following clinical data will be
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collected in NAChO: age, gender, ethnicity, major preexisting
comorbidities and medication, clinical scores (Acute Physiology
and Chronic Health Evaluation II, Simpliﬁed Acute Physiology
Score II, Sepsis-related Organ Failure Assessment score), date of
hospital and ICU admission, routine laboratory data, days on any
renal replacement therapy (RRT), days on mechanical ventila-
tion, days on catecholamines, cumulative dose of muscle
relaxants, cumulative dose of analgosedatives, cumulative dose
of catecholamines, cumulative steroid dose.
The clinical database developed for this study comply with the
Good Clinical Practices (GCP) predicate rule requirements, laws
and regulations (Personal data protection) and allows an audit of
actions performed by users. All data modiﬁcations will be
documented in an audit trail ﬁle. After the last veriﬁcation, the
relevant data will be locked. The system is compliant with e-
signature laws (particularly the Title 21 CFR Part 11 of the Code
of Federal Regulations). All eCRF data will be validated by a
Clinical Data Manager. Computerized edit checks programmed
to validate the data will be performed with data discrepancies
triggering automatic queries.
3.8. Trial monitoring
Trial monitoring is performed by the Clinical Trials Unit (CTU) of
the University of Bern, Switzerland. Monitoring of trial data and
documentation ensures that protocol requirements, applicable local
laws, ICH guidelines, and Investigator obligations are fulﬁlled.
3.9. Safety
Due to the observational nature of the trial, adverse events (AEs)
will be reported only for unusual undesired medical events that
seem unrelated or atypical to the underlying critical disease. As
critically ill patients may experience potential life threatening
events by deﬁnition, severe adverse events (SAEs) will be reported
in cases of death on the ICU only. SAEs related to study
procedures will be reported also.
3.10. Statistical analysis
Baseline considerations: Patients entering the study at day 5 are
considered ICU long stayers. It is expected to have around 50 to
60% of the patients still at the ICU at day 14. The main objective
is to characterize the change from baseline (deﬁned as day 5) for
nutrient levels in blood of patients with andwithout ICU-AWand
in “sepsis group” vs “CNS group”. Primary characterization of
interest is change of nutrient levels in blood (plasma/serum) from
baseline (day 6) to day 14 (visit 7). Characterization of the change
from baseline (day 6) of nutrient levels in blood (plasma/serum)
over the ensuing days will be of supportive interest. Secondary
objectives are to characterize the change of nutrient levels in
muscle and in urine from baseline to day 14, day 22 and day 30 in
patients with vs without ICU-AW and in “sepsis group” vs “CNS
group”.
All statistical analyses will be performed using either SAS 9.3
(or higher) or R 3.0 (or higher). Baseline characteristics will be
described for all patients on the full analysis set. Summary
statistics for primary and secondary endpoints will be described
for all patients on the full analysis set at baseline and at each post
baseline visit. Continuous variables will be summarized using the
following descriptive statistics:
 For approximately normally distributed variable, the number
of non-missing values, the arithmetic mean, the arithmetic
standard deviation, the minimum and the maximum values.
 For approximately log-normally distributed variables, the
number of non-missing values, the geometric mean, the
geometric standard deviation, the minimum and the maximum
values.
 For non-normally and non-log-normally distributed variable,
the number of non-missing values, the median, the 25th and
75th percentiles, the minimum and the maximum values.
Categorical variables will be summarized using frequencies
and percentages (out of total number of non-missing values).
Unless otherwise speciﬁed, each test will be performed using a
signiﬁcance level of 5%. Each model based statistic will be
presented both with the associated 2-sided 95% conﬁdence
interval and two-sided P value. Nomultiplicity adjustment will be
considered. Based on current results, data will be controlled for
quality. Extreme outliers will be detected based on inter-quartile
range (IQR) detection. Based on the proportion of missing values,
variables will be considered for inclusion or exclusion from
subsequent analysis.
3.10.1. Primary analyses. For each nutrient level in blood
(plasma/serum) of ICU long stayer patients, the change from
baseline to day 14 (visit 7) will ﬁrst be analyzed using a linear
model, adjusting (but not restricted to) for nutrient level at day 6
and ICU admission condition (“sepsis group” or “CNS group”)
aiming to evaluate the difference between ICU long stayers in sepsis
and ICU long stayers in the CNS group. In a secondmodel, change
from baseline for nutrient level at day 14 will be analyzed using a
linear model, adjusting (but not restricted to) for nutrient level at
day 6 and the ICU-AW status aiming in evaluating the difference
between patient with and without ICU-AW. Note that these
analyses of the change from baseline for nutrient levels in blood
maybecombinedwith the change frombaseline innutrient levels in
blood observed at other relevant subsequent visit using a linear
mixed models or an ANOVA for repeated measures approach. In
case of severe deviation from the normality hypothesis, log
transformation or Box-Cox transformation may be applied.
Interaction between ICU admission condition and ICU-AW status
may be considered in these linear models as an explanatory
analyses. The following SAS code may be used when change from
baseline at day 14 is analyzed alone: PROCMIXEDDATA= ICU;
CLASS cond;MODELCHG=BASE cond /S; RUN;where cond is
the variable indicating the conditionof the ICUpatient, BASE is the
baseline measurement, CHG the change from baseline and ICU is
the dataset containing all these variables.
As the number of patients in the CNS group who will die or be
discharged from ICU may be different from the number of
patients in the sepsis group, a competing risk analysis on these 2
populations will be performed as supportive analyses. If the risks
for both patient populations are similar, we may have more
conﬁdence in any ﬁnding of the ANCOVA model. The initial
states are patients at day 6 in “sepsis group” or “CNS group”.
The cumulative incidence function will be calculated for ICU-AW
and for ICU discharge or death (no distinction between discharge
and death). The Aalen-Johansen estimator will be used. A
proportional sub-distribution hazard model according to Fine
and Gray[30] on the event of interest ICU-AW, stratiﬁed by
diagnosis (sepsis or CNS at ICU admission) with variable
selection by boosting as previously proposed.[31] Variables which
undergo boosting are the ones of the nutrient proﬁle measured at
day 6 (ﬁrst competing risk analysis) and changes from baseline at
day 14 for the nutrient proﬁle (second competing risk analysis).
Boosting will preferably be performed with the R package
CoxBoost available on the CRAN.
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3.10.2. Secondary analyses. Similar statistical approaches to
the primary analyses will be used to evaluate nutritional and
metabolic signatures in urine and muscle (if available) of ICU-
long stayers:
 The change from baseline to day 14 will be analyzed using a
linear model, adjusting (but not restricted to) for nutrient level
at day 6 and ICU admission condition (“sepsis group” or “CNS
group”);
 The change from baseline to day 14 will be analyzed using a
linear model, adjusting (but not restricted to) for nutrient level
at day 6 and the ICU-AW status; Note that these analyses of the
change from baseline for nutrient levels in muscle and urine
may be combined with the change from baseline in nutrient
levels observed at other relevant subsequent visit using in linear
mixed models or an ANOVA for repeated measures approach.
In case of severe deviation from the normality hypothesis, log
transformation or Box-Cox transformation may be applied.
Interaction between ICU admission condition and ICU-AW
status may be considered in these linear models as an additional
explanatory variable.
3.10.3. Exploratory analyses. Exploratory analyses will be
ﬁnalized in the Statistical Analysis Plan.
3.11. Power analysis
This is a prospective observational trial with 50 patients with
severe sepsis/septic shock (“sepsis group”) with an expected high
incidence of ICU-AW and 50 patients (“CNS group”) with an
expected low incidence of ICU-AW. Due to the observational
non-interventional and exploratory nature (estimation of effect
size is the focal point) of the study, a formal power calculation
was refrained from as it was not deemed useful.
3.12. Timeline
2016–2017: Finalization of research strategy, ﬁnalization of
protocol, approvals
2017–2019: First patient in, estimated end of trial in 2019
Q3-Q4 2019: Analysis of trial results and publication
3.13. Publication/authorships
Before publication of the trial results in an academic journal, a
publication committee will be formed which will includemembers
of the involved parties and which will be chaired by the principle
investigator. A main publication (eg, termed “Nutrient pattern
Analysis in critically ill patients usingOmics technology (NAChO)-
a single-center prospective observational trial”) will aim to
summarize key clinical and laboratory ﬁndings as well as nutrient
patterns. In this main publication, the ﬁrst and corresponding
author will be the Principle investigator and the last author will be
another member of the clinical team. Co-Authorship will be
granted on the basis of personal input in accordance to Vancouver
deﬁnitions. If applicable, additional publications (eg, on MRI
results, electrophysiological ﬁndings, and/or detailed course of
speciﬁc nutrient or lab markers/patterns) will include members of
all involved parties and authorship will be granted on the basis of
personal input in accordance to Vancouver deﬁnitions.
4. Discussion
Previous data indicate that intensive care unit (ICU)- acquired
weakness (ICU-AW) signiﬁcantly affects morbidity and mortality
rates of affected critically ill patients.[2,3,6] However, metabolic
changes in respective patients and how sepsis may inﬂuence them
is largely unknown. We thus investigate underlying nutritional
and muscular patterns in septic and non-septic long staying ICU
patients with/without ICU-AW that receive enteral nutrition
using a standard liquid enteral formula. Using comprehensive
nutrient analysis, we will assess changes in nutrient patterns in
blood (plasma/serum), urine, and muscular tissue (if available)
over time in critically ill patients with the aim to identify ICU-
AW-speciﬁc nutrient patterns. NAChO data and respective
computational models will allow for a better and more detailed
understanding of metabolic changes in critically ill patients
and will likely open up new avenues for future therapeutic and
nutritional interventions.
4.1. Strengths and limitations
Comprehensive assessment of nutrients and metabolic indices,
including amino acids, fatty acids, organic acids, vitamins,
minerals, routine clinical parameters, immune function markers
including analysis of immune system/metabolic interface, indistinct
biological matrices (blood plasma/serum, urine, muscle) was
previously not performed in critically ill patients. In the light of
the speciﬁc patient population included, the sample size may be
considered large. Following comprehensive analysis,wewill beable
to identify novel metabolic and nutrient patterns using sophisticat-
ed computational models. The exploratory nature of the trial will
allow for hypothesis driving in multiple areas of nutritional/
metabolic research, and this is regarded as major strength.
A number of limitations apply that deserve discussion. First,
this is a single-center trial with a somewhat limited number (n=
100) of critically ill patients. Although this may be the ﬁrst larger
analysis to generate comprehensive nutrient pattern data in
critically ill patients, and following expert statistical consultation,
a formal sample size calculation was deliberately refrained from.
The focal point of the current exploratory observational trial is
estimation of effect sizes. Second, collection of samples was
deliberately chosen to start late, that is, in ICU patients with
prolonged length of stay (“ICU long stayers”). This was
performed as respective ICU long stayers are the population of
critically ill patients with a particular high morbidity and
mortality, high resource use, and a high incidence of ICU-AW. It
is speculated that this population may beneﬁt most from
respective therapeutic interventions. Third, as in all observational
studies, underlying molecular mechanism can only be concluded
on in further studies, for example, from muscle tissues. Thus,
associations and patterns rather than molecular mechanisms will
be explored. Fourth, only patients with CNS disorders and/or
sepsis are included, precluding a formal control group. However,
we deliberately choose to include a group of critically ill patients
with a presumed high incidence (“sepsis group”) and low
incidence (“CNS group”) of ICU-AW. Finally, the amount of
liquid enteral nutrition delivered to each individual patient might
not always be the same and might theoretically impact the results
across groups. Nevertheless, the amount of enteral nutrition/
caloric intake will typically be adapted to the results of indirect
calorimetric measurements. Importantly, the chosen enteral
liquid nutritional intake regimen may best reﬂect clinical reality
rather than any artiﬁcial trial conditions.
4.2. Trial status
The trial is currently actively recruiting patients. Completion of
patient recruitment is expected for Q1-Q2 of 2019.
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